1
|
Li S, Wang Y, Xu G, Xu Y, Fu C, Zhao Q, Xu L, Jia X, Zhang Y, Liu Y, Qiao J. The combination of allicin with domiphen is effective against microbial biofilm formation. Front Microbiol 2024; 15:1341316. [PMID: 38873153 PMCID: PMC11169630 DOI: 10.3389/fmicb.2024.1341316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 05/15/2024] [Indexed: 06/15/2024] Open
Abstract
Background Microorganisms in biofilms are particularly difficult to control because of their increased survival and antibiotic resistance. Allicin and domiphen were employed to inhibit the microbial growth and biofilm formation of Staphylococcus aureus, Escherichia coli, and Candida albicans strains. Methods Broth microdilution method and checkerboard assay were conducted to determine the efficacy of allicin combined with domiphen against S. aureus, E. coli, and C. albicans. Microbial biofilm formation was measured using the crystal violet staining method and fluorescence microscopy. And the total viable count of the biofilm cells on material surface after the treatment with antimicrobial reagents was calculated with the plate count technique. Results The two drugs showed synergistic effects against the pathogens with a fractional bactericidal concentration of less than 0.38. The combination of 64 μg/mL allicin with 1 μg/mL domiphen dispersed over 50% of the biofilm mass of S. aureus, E. coli, and C. albicans. In addition, the drug combination reduced the total viable counts of E. coli and C. albicans biofilm cells on stainless steel and polyethylene surfaces by more than 102 CFU/mL. Conclusion The combination of allicin and domiphen is an effective strategy for efficiently decreasing biofilms formation on various industrial materials surfaces.
Collapse
Affiliation(s)
- Shang Li
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Yutong Wang
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Geweirong Xu
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Yuqing Xu
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Cuiyan Fu
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Quanlin Zhao
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Linjie Xu
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Xinzhou Jia
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Yumeng Zhang
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
| | - Yi Liu
- Department of Biophysics, School of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
- School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Jiaju Qiao
- Department of Biotechnology, School of Life Sciences, Xuzhou Medical University, Xuzhou, China
- Department of Biophysics, School of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China
| |
Collapse
|
2
|
Zhao R, Jiang S, Ren S, Yang L, Han W, Guo Z, Gu J. A novel phage putative depolymerase, Depo16, has specific activity against K1 capsular-type Klebsiella pneumoniae. Appl Environ Microbiol 2024; 90:e0119723. [PMID: 38551353 PMCID: PMC11022553 DOI: 10.1128/aem.01197-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 03/10/2024] [Indexed: 04/18/2024] Open
Abstract
Klebsiella pneumoniae, especially hypervirulent K. pneumoniae (hvKP), is a common opportunistic pathogen that often causes hospital- and community-acquired infections. Capsular polysaccharide (CPS) is an important virulence factor of K. pneumoniae. Some phages encode depolymerases that can recognize and degrade bacterial polysaccharides. In this study, the lytic bacteriophage vB_KpnP_ZK1 (abbreviated as ZK1) was isolated using serotype K1 hvKP as the host. Although amino acid sequence BLAST analysis indicated that the tail fiber protein Depo16 of phage ZK1 showed no significant similarity to any reported phage depolymerases, it displayed enzymatic activities that are characteristic of phage depolymerases. After expression and purification, Depo16 could efficiently remove the capsular polysaccharide layer that surrounds the surface of serotype K1 K. pneumoniae. Although no bactericidal activity was detected, Depo16 makes serotype K1 K. pneumoniae sensitive to peritoneal macrophages (PMs). In addition, in a mouse bacteremia model of serotype K1 K. pneumoniae, 25 µg of Depo16 was effective in significantly prolonging survival. Depo16 treatment can reduce the bacterial load in blood and major tissues and alleviate tissue damage in mice. This indicates that the putative depolymerase Depo16 is a potential antibacterial agent against serotype K1 K. pneumoniae infections.IMPORTANCEKlebsiella pneumoniae often causes hospital-acquired infections and community-acquired infections. Capsular polysaccharide (CPS) is one of the crucial virulence factors of K. pneumoniae. K1 and K2 capsular-type K. pneumoniae strains are the most prevalent serotypes of hypervirulent K. pneumoniae (hvKP). In this study, a novel K. pneumoniae phage named vB_KpnP_ZK1 was isolated, and its putative depolymerase Depo16 showed low homology with other reported phage depolymerases. Depo16 can specifically degrade the K. pneumoniae K1 capsule making this serotype sensitive to peritoneal macrophages. More importantly, Depo16 showed a significant therapeutic effect in a mouse bacteremia model caused by serotype K1 K. pneumoniae. Thus, Depo16 is a potential antibacterial agent to combat serotype K1 K. pneumoniae infections.
Collapse
Affiliation(s)
- Rihong Zhao
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
| | - Shanshan Jiang
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
| | - Siyu Ren
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
| | - Li Yang
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
| | - Wenyu Han
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
| | - Zhimin Guo
- Clinical Laboratory Department, Infectious Diseases and Pathogen Biology Center, First Hospital of Jilin University, Changchun, China
| | - Jingmin Gu
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China
- Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China
| |
Collapse
|
3
|
Liu S, Li H, Zhu Z, Wu M, Jin M, Wang X, Hou J, Li D, Wang R. A bacteriophage against Citrobacter braakii and its synergistic effect with antibiotics. Arch Microbiol 2024; 206:74. [PMID: 38253939 DOI: 10.1007/s00203-023-03803-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 12/06/2023] [Accepted: 12/17/2023] [Indexed: 01/24/2024]
Abstract
A bacteriophage BD49 specific for Citrobacter braakii was screened out and purified by double-layer plate method. It consists of a polyhedral head of 93.1 ± 1.2 nm long and 72.9 ± 4.2 nm wide, tail fibers, collar, sheath and baseplate. The bacteriophage was identified by morphology observed with transmission electron microscope (TEM), whole genome sequencing carried out by Illumina next generation sequencing (NGS) technique, and gene annotation based on Clusters of Orthologous Groups of proteins (COG) database. It was identified primarily as a member of Caudovirales by morphology and further determined as Caudovirales, Myoviridae, and Citrobacter bacteriophage by alignment of its whole genome sequence with the NCBI database and establishment of phylogenetic tree. The bacteriophage showed good environmental suitability with optimal multiplicity of infection (MOI) of 0.01, proliferation time of 80 min, optimum living temperature of 30-40 °C, and living pH of 5-10. In addition, it exhibited synergistic effect with ciprofloxacin against C. braakii in antibacterial tests.
Collapse
Affiliation(s)
- Siqi Liu
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Hanyi Li
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Zhihao Zhu
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Mengjiao Wu
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Mingxuan Jin
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Xiangxiang Wang
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China
| | - Jincai Hou
- Hebei Shineway Pharmaceutical Co., Ltd, Yingbin Street, Langfang, 065201, Hebei, China.
| | - Dan Li
- Hebei Shineway Pharmaceutical Co., Ltd, Yingbin Street, Langfang, 065201, Hebei, China.
| | - Rufeng Wang
- School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.
| |
Collapse
|